Lung Transplantation for Lymphangioleiomyomatosis in Japan
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Lung transplantation has been established as the definitive treatment option for patients with advanced lymphangioleiomyomatosis (LAM). However, the prognosis after registration and the circumstances of lung transplantation with sirolimus therapy have never been reported. METHODS: In this national survey, we analyzed data from 98 LAM patients registered for lung transplantation in the Japan Organ Transplantation Network. RESULTS: Transplantation was performed in 57 patients as of March 2014. Survival rate was 86.7% at 1 year, 82.5% at 3 years, 73.7% at 5 years, and 73.7% at 10 years. Of the 98 patients, 21 had an inactive status and received sirolimus more frequently than those with an active history (67% vs. 5%, p<0.001). Nine of twelve patients who remained inactive as of March 2014 initiated sirolimus before or while on a waiting list, and remained on sirolimus thereafter. Although the statistical analysis showed no statistically significant difference, the survival rate after registration tended to be better for lung transplant recipients than for those who awaited transplantation (p = 0.053). CONCLUSIONS: Lung transplantation is a satisfactory therapeutic option for advanced LAM, but the circumstances for pre-transplantation LAM patients are likely to alter with the use of sirolimus.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fewer patients with LAM have required lung transplant since the standardized use of mTOR inhibitors as treatment, but it remains an indication for those with severely abnormal lung function (FEV1 < 30%), exertional dyspnea (NYHA class III or IV), or hypoxemia at rest.(303–306, 308–315)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [303]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While disease recurrence does occur post-transplant, it does not appear to limit survival.(303, 304, 309, 311, 316–318)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [303]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although lymphangioleiomyomatosis (LAM) is not a common indication for transplantation, it has better outcomes after transplantation than other diseases.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [63]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the current consensus is that they should be used until transplantation is considered, and the patient should be thoroughly educated about the risks involved [63-65].”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [63]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Even though it is rare for LAM patients to require transplantation owing to the use of the mechanistic target of rapamycin (mTOR) inhibitors”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [63]
Experimental — accuracy not yet measured
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guidelines for the diagnosis and treatment of pulmonary hypertension
(2009) · European Respiratory Journal · doi:10.1183/09031936.00139009 · Cited by 1,300
Regulation of the mTOR Complex 1 Pathway by Nutrients, Growth Factors, and Stress
Sengupta, S., Peterson, T. R., & Sabatini, D. M. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.026 · Cited by 1,241 · cited 1×
“Sirolimus, an mTOR inhibitor, blocks mTORC1-mediated activation and restores homeostasis [9].”
BackgroundEfficacy and safety of sirolimus in lymphangioleiomyomatosis
McCormack, F. X., Inoue, Y., Moss, J., Singer, L. G., Strange, C., Nakata, K., Barker, A. F., Chapman, J. T., Brantly, M. L., Stocks, J. M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1100391 · Cited by 1,099
Self-citationKwiatkowski, D. J. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.5.525 · Cited by 667
Carsillo, T., Astrinidis, A., & Henske, E. P. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.11.6085 · Cited by 646
European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis
Johnson, S. R., Cordier, J. F., Lazor, R., Cottin, V., Costabel, U., Harari, S., Reynaud-Gaubert, M., Boehler, A., Brauner, M., Popper, H., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00076209 · Cited by 590 · cited 1×
“Lymphangioleiomyomatosis (LAM) is a rare neoplastic disease, characterized by the proliferation of abnormal smooth muscle-like cells (LAM cells), which lead to cystic destruction of the lungs, chylous effusions and the formation of lymphangioleiomyomas [1].”
BackgroundYusen, R. D., Christie, J. D., Edwards, L. B., Kucheryavaya, A. Y., Benden, C., Dipchand, A. I., Dobbels, F., Kirk, R., Lund, L. H., Rahmel, A. O., et al. (2013) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2013.08.007 · Cited by 506 · cited 2×
“Our study, the first national survey of lung transplantation for LAM patients in Japan, revealed that this group’s survival rate after transplantation was more favorable than that of patients with other indications [7, 8] and also better than recorded in the registry of The International Society for Heart and Lung Tra…”
BackgroundResultTuberin Regulates p70 S6 Kinase Activation and Ribosomal Protein S6 Phosphorylation
Goncharova, E. A., Goncharov, D. A., Eszterhas, A., Hunter, D. S., Glassberg, M. K., Yeung, R. S., Walker, C. L., Noonan, D., Kwiatkowski, D. J., Chou, M. M., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202678200 · Cited by 425
Guidelines for the diagnosis and treatment of pulmonary hypertension
Galie, N., Hoeper, M. M., Humbert, M., Torbicki, A., Vachiery, J.-L., Barbera, J. A., Beghetti, M., Corris, P., Gaine, S., Gibbs, J. S., et al. (2012) · Revista Portuguesa de Cardiologia (English Edition) · doi:10.1016/j.repce.2011.10.006 · Cited by 257
Lung Transplantation for Lymphangioleiomyomatosis
Boehler, A., Speich, R., Russi, E. W., & Weder, W. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610243351704 · Cited by 217
Research works printed but not linked: 1
- J Groetzner, 2004, Airway anastomosis complications in de novo lung transplantation with sirolimus-based immunosuppression, J Heart Lung Transplant, 23, 632, 10.1016/S1053-2498(03)00309-7 · DOI · Paper page
Cited by
Leard, L. E., Holm, A. M., Valapour, M., Glanville, A. R., Attawar, S., Aversa, M., Campos, S. V., Christon, L. M., Cypel, M., Dellgren, G., et al. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.07.005 · Cited by 821
Lymphangioleiomyomatosis: pathogenesis, clinical features, diagnosis, and management
McCarthy, C., Gupta, N., Johnson, S. R., Yu, J. J., & McCormack, F. X. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00228-9 · Cited by 209
Lymphangioleiomyomatosis: a clinical review
O'Mahony, A. M., Lynn, E., Murphy, D. J., Fabre, A., & McCarthy, C. (2020) · Breathe · doi:10.1183/20734735.0007-2020 · Cited by 56
“Once a fatal disease with lung transplantation as the only treatment option, mTOR inhibitors have been shown to slow loss of lung function in LAM [67].”
BackgroundKhawar, M. U., Yazdani, D., Zhu, Z., Jandarov, R., Dilling, D. F., & Gupta, N. (2019) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2019.06.015 · Cited by 45
Spontaneous pneumothorax in diffuse cystic lung diseases
Cooley, J. C., Lee, G., & Gupta, N. (2017) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000391 · Cited by 43
Tuberous sclerosis complex for the pulmonologist
Rebaine, Y., Nasser, M., Girerd, B., Leroux, C., & Cottin, V. (2021) · European Respiratory Review · doi:10.1183/16000617.0348-2020 · Cited by 38
Single lung transplantation for lymphangioleiomyomatosis: a single-center experience in Japan
Oishi, H., Watanabe, T., Matsuda, Y., Noda, M., Ejima, Y., Saiki, Y., Seyama, K., Kondo, T., & Okada, Y. (2018) · Surgery Today · doi:10.1007/s00595-018-1678-z · Cited by 17
Self-citationFrench recommendations for the diagnosis and management of lymphangioleiomyomatosis
Cottin, V., Blanchard, É., Kerjouan, M., Lazor, R., Reynaud‐Gaubert, M., Taillé, C., Uzunhan, Y., Wémeau-Stervinou, L., Andréjak, C., Baud, D., et al. (2023) · Respiratory Medicine and Research · doi:10.1016/j.resmer.2023.101010 · Cited by 24
Recent advances in the pathobiology and clinical management of lymphangioleiomyomatosis
Harari, S. A., Spagnolo, P., Cocconcelli, E., Luisi, F., & Cottin, V. (2018) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000502 · Cited by 19
Baldi, B. G., Samano, M. N., Campos, S. V., de Oliveira, M. R., Junior, J. E. A., Carraro, R. M., Teixeira, R. H. O. B., Minguini, I. P., Burlina, R., Pato, E. Z. S., et al. (2017) · Lung · doi:10.1007/s00408-017-0045-y · Cited by 16
“These survival rates are similar to those observed in recent studies from different countries and greater than those observed in older studies [8, 10, 12, 14].”
ResultKurosaki, T., Otani, S., Miyoshi, K., Okazaki, M., Sugimoto, S., Suno, M., Yamane, M., Kobayashi, M., Oto, T., & Toyooka, S. (2020) · The Clinical Respiratory Journal · doi:10.1111/crj.13108 · Cited by 15
Lung transplantation for lymphangioleiomyomatosis
Warrior, K., & Dilling, D. F. (2022) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2022.09.021 · Cited by 15
Recurrence of primary disease following lung transplantation
Esendagli, D. R., Ntiamoah, P., Küpeli, E., Bhardwaj, A., Ghosh, S., Mukhopadhyay, S., & Mehta, A. C. (2022) · ERJ Open Research · doi:10.1183/23120541.00038-2022 · Cited by 14
Recent advances in the management of lymphangioleiomyomatosis
Xu, K., Tian, X., & Ryu, J. H. (2018) · F1000Research · doi:10.12688/f1000research.14564.1 · Cited by 13
Cystic Lung Disease in Genetic Syndromes with Deficient Tumor Suppressor Gene Function
Daccord, C., Nicod, L. P., & Lazor, R. (2017) · Respiration · doi:10.1159/000485106 · Cited by 12
Zhang, J., Liu, D., Yue, B., Ban, L., Zhou, M., Wang, H., Lv, J., Wu, B., Zhai, Z., Xu, K., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.584826 · Cited by 11
“In the present cohort, the waiting time of patients seemed relatively shorter than the Japanese center’s interval, partly due to the donation volume and the endurance of the patients (17).”
BackgroundJohnson, S. R. (2023) · Springer eBooks · doi:10.1007/978-3-031-12950-6_19 · Cited by 11
Indications for Lung Transplantation and Patient Selection
Son, J., & Shin, C. (2022) · Journal of Chest Surgery · doi:10.5090/jcs.22.057 · Cited by 10
“The use of mTOR inhibitors in patients being considered for transplantation remains a matter of debate, but the current consensus is that they should be used until transplantation is considered, and the patient should be thoroughly educated about the risks involved [63-65].”
BackgroundKumondai, M., Kikuchi, M., Mizuguchi, A., Hayashi, N., Ui, M., Hirama, T., Okada, Y., Sato, Y., Sato, T., Maekawa, M., et al. (2023) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.2023.j016 · Cited by 7
Self-citationChang, S., Choi, J. S., Leem, A. Y., Lee, S. H., Lee, S. H., Kim, S. Y., Chung, K. S., Jung, J. Y., Kang, Y. A., Kim, Y. S., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-12314-1 · Cited by 9
A narrative review on the management of patients awaiting lung transplantation in Japan
Suzuki, H., & Yoshino, I. (2023) · Journal of Thoracic Disease · doi:10.21037/jtd-22-1690 · Cited by 4
“LAM is a rare neoplastic disease characterized by the proliferation of abnormal smooth muscle-like cells, leading to cystic destruction of the lungs.”
InfluentialTaveira‐DaSilva, A. M., Gopalakrishnan, V., Yao, J., Chen, M. Y., Julien-Williams, P. A., Jones, A. M., Pacheco–Rodriguez, G., & Moss, J. (2022) · BMC Pulmonary Medicine · doi:10.1186/s12890-022-02123-7 · Cited by 6
“This is in part due to the fact that the severity of symptoms in patients with LAM at rest is highly variable and lung transplantation still has significant morbidity, expenses, and relatively low long-term survival [14, 29].”
BackgroundInfluentialBeyond the Graft: Recurrence of Interstitial Lung Diseases Post Transplant
Ntiamoah, P., & Mehta, A. C. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041093 · Cited by 4
Sakurai, T., Kanou, T., Funaki, S., Fukui, E., Kimura, T., Ose, N., Inoue, Y., & Shintani, Y. (2024) · Respiratory Investigation · doi:10.1016/j.resinv.2024.05.008 · Cited by 2
Self-citationBrazilian Thoracic Association recommendations for the management of lymphangioleiomyomatosis
Baldi, B. G., Feitosa, P. H. R., Rubin, A. S., Amaral, A. F., Freitas4, C. S. G., da Costa, C. H., Mancuzo, E. V., do Nascimento, É. C. T., Araújo, M. S., Rocha, M. J. J., et al. (2025) · Jornal Brasileiro de Pneumologia · doi:10.36416/1806-3756/e20240378 · Cited by 4
The Role of Surveillance Bronchoscopy Following a Lung Transplantation
Mohamed, S., Tosi, D., Pieropan, S., Cara, A., Caffarena, G., Croci, G. A., & Rosso, L. (2020) · OBM Transplantation · doi:10.21926/obm.transplant.2004129 · Cited by 2
Ayen, A. A., Mihretu, D. D., Getahun, A. M., Kassa, B. D., Bezabih, F., & Shumet, A. (2025) · International Journal of Surgery Case Reports · doi:10.1016/j.ijscr.2025.111913 · Cited by 1
“There are multiple bilateral diffuse uniformly distributed well defined small cystic lesions involving the whole lung bilaterally with no volume loss. lung transplantation may be considered as a last resort [23].”
Huang, Y.-L., Chen, P.-R., Lai, Y., & Hsu, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168564 · Cited by 1
“Although emerging evidence has revealed the efficacy of sirolimus in LAM disease, some patients treated with sirolimus still progress, and only lung transplantation (LT) remains a standard treatment option for patients with advanced-stage LAM [18].”
BackgroundSathirareuangchai, S., Weon, J. L., Tintle, S. J., Batra, K., Yan, S. X., & Torrealba, J. R. (2021) · Surgical and Experimental Pathology · doi:10.1186/s42047-021-00095-2 · Cited by 1
“(Ando et al. 2016; Benden et al. 2009; Pechet et al. 2004) Previously reported cases of recurrent LAM in the lung allograft are shown in Table 1.”
BackgroundInfluentialPerioperative management of thoracic surgery in patients with lymphangioleiomyomatosis
Fukui, M., Seyama, K., Matsunaga, T., Hattori, A., Takamochi, K., Oh, S., Kawagoe, I., & Suzuki, K. (2022) · Surgical Case Reports · doi:10.1186/s40792-022-01507-5 · Cited by 1
“At present, all lung transplantation centers in Japan consider it mandatory for LAM patients to quit taking sirolimus prior to lung transplantation [23].”
BackgroundSelf-citationJackson, E., & Nichani, R. (2017) · Journal of the Intensive Care Society · doi:10.1177/1751143717718663
“It should be noted that this is significantly higher than other studies.(7) Our case is unusual as there are no recorded cases of the initial presentation of LAM occurring as cardiac arrest.”
ResultAddressing the challenges of lymphangioleiomyomatosis assessment in the clinic
Taveira‐DaSilva, A. M., & Moss, J. (2017) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2017.1400966
“A recent report from Japan described the course of 57 patients who had undergone lung transplantation [43].”
BackgroundMechanical pleurodesis is not a contraindication to lung transplantation
Thibodeau, A. (2018) · Clinical Research in Practice The Journal of Team Hippocrates · doi:10.22237/crp/1518739440
“” Six relevant studies evaluating lung transplant outcomes following pleurodesis in specific populations were returned, two of which address the issue in patients with a history of cystic fibrosis, and three of which focus on patients with lymphangioleiomyomatosis—two lung diseases with a predilection for recurrent pn…”
BackgroundLungentransplantation bei seltenen Lungenerkrankungen
Gottlieb, J., & Besa, V. (2022) · Springer eBooks · doi:10.1007/978-3-662-63651-0_7
Transplantation pulmonaire et lymphangioléiomyomatose
Reynaud‐Gaubert, M., Pavec, J. L., & Uzunhan, Y. (2023) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2023.01.023
Taveira‐DaSilva, A. M., Gopalakrishnan, V., Yao, J., Chen, M. Y., Julien-Williams, P. A., Jones, A. M., Pacheco–Rodriguez, G., & Moss, J. (2022) · Figshare · doi:10.6084/m9.figshare.21203398
Metadata
- Authors
- Ando, K., Okada, Y., Akiba, M., Kondo, T., Kawamura, T., Okumura, M., Chen, F., Date, H., Shiraishi, T., Iwasaki, A., Yamasaki, N., Nagayasu, T., Chida, M., Inoue, Y., Hirai, T., Seyama, K., Mishima, M., & Respiratory Failure Research Group of the Japanese Ministry of Health, L.
- Affiliations
- Juntendo University (JP)
- Tohoku University (JP)
- The University of Osaka (JP)
- Kyoto University (JP)
- Fukuoka University (JP)
- Nagasaki University (JP)
- Dokkyo University (JP)
- Ministry of Health Labour and Welfare (JP)
- Corresponding author
- Seyama, Kuniaki
- ORCID
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-01-15
- Volume
- 11
- Issue
- 1
- Pages
- e0146749
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4714890
- OpenAlex
- W2247267173
- Cited by
- 37
- References
- 30
- Citations by year
- 2025: 3 · 2024: 1 · 2023: 5 · 2022: 8 · 2021: 6 · 2020: 3 · 2019: 2 · 2018: 4 · 2017: 5
- FWCI
- 2.95
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Kyoto University Research Information Repository (Kyoto University) (submittedVersion, cc-by)
- Funders
- Nihon University
- Keio University
- Ministry of Health, Labour and Welfare
- University of Tokyo
- Hokkaido University
- Chiba University
- Tokyo Women's Medical University
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Tuberous Sclerosis Complex Research
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Medical Imaging and Pathology Studies
- Keywords
- lymphangioleiomyomatosis, lung transplantation, rapamycin, transplant recipient survival, transplant waiting list
- MeSH terms
- Adult, Anti-Bacterial Agents, Female, Humans, Japan, Lung Neoplasms, Male, Middle Aged, Retrospective Studies, Survival Rate, Lung Transplantation, Lymphangioleiomyomatosis, Sirolimus, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.